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The constitutively active G-protein-coupled receptor and
viral oncogene ORF74, encoded by Kaposi sarcoma-associated
herpesvirus (human herpesvirus 8), binds a broad range of che-
mokines, including CXCL1 (agonist), CXCL8 (neutral ligand),
and CXCL10 (inverse agonist). Although chemokines interact
with the extracellular N terminus and loops of the receptor, we
demonstrate that helix 8 (Hx8) in the intracellular carboxyl tail
(C-tail) of ORF74 directs chemokine binding. Partial deletion of
theC-tail resulted inaphenotypewithreducedconstitutiveactivity
but intact regulation by ligands. Complete deletion of the C-tail,
includingHx8, resulted in an inactivephenotype that lacksCXCL8
binding sites and has an increased number of binding sites for
CXCL10. Similar effects were obtained with the single R7.61322W
or Q7.62323P mutations in Hx8. We propose that the conserved
charged or polar side chain at position 7.61 has a specific role in
stabilizing the endof transmembranedomain7 (TM7).Disruption
of Hx8 by deletion or mutation distorts an H-bonding network,
involving highly conserved amino acids within TM2, TM7, and
Hx8, that is crucial for positioning of theTMdomains, coupling to
Gq, andCXCL8binding. Thus,Hx8 appears to exert a key role in
receptor stabilization through the conserved residueR7.61, direct-
ing the ligandbindingprofile ofORF74and likely also that of other
class AG-protein-coupled receptors.
Viral G-protein-coupled receptors (GPCRs)3 have attracted
considerable attention over the past few years. Although for
most viral GPCRs, their role in viral pathogenesis still has to be
elucidated, for the Kaposi sarcoma-associated herpesvirus-en-
coded receptor ORF74, a clear link to Kaposi sarcoma has been
established (1). Due to their homology with human chemokine
receptors and the acquisition of additional properties, such as
constitutive activity and promiscuous G-protein coupling and
chemokine binding, viral GPCRs provide unique insight in the
molecular mechanisms of chemokine receptor function.
ORF74 shares homology with the CXC chemokine receptor
family and with CXCR2 in particular (see Ref. 2 for an overview
of chemokine receptors and nomenclature). In general, human
chemokine receptors bind only a subset of chemokines. Inter-
estingly,ORF74 binds a broad range of chemokineswith unique
pharmacology. Several CXCR2 ligands act as agonist (e.g.
CXCL1/GRO (growth-related oncogene )), partial agonist,
neutral ligand (e.g. CXCL8/IL-8 (interleukin-8)), or inverse
agonist. Both CXCR3 and CXCR4 ligands, CXCL10/IP-10
(-interferon-inducible protein-10) and CXCL12/SDF-1
(stromal cell-derived factor 1-), respectively, act as inverse
agonists (3). Previously, it was demonstrated that both CXCL1
and CXCL10 bind with high affinity either to a common con-
formation of ORF74 or to readily interconvertible states, not
available for the neutral ligand CXCL8 (3). Also, for other class
A GPCRs known to bind more than one ligand, e.g. the tachy-
kinin NK1 receptor (4) and chemokine receptors CXCR2 (5),
CXCR3 (6), andUS28 (7), bindingmodes appear clearly distinct
for the different ligands. This phenomenon is associated with
the inability of some of these ligands to displace each other
and/or a clear difference in the apparent number of binding
sites (Bmax), suggesting that these ligands bind to distinct recep-
tor populations (8). For chemokine receptors, the binding
mode is defined by interaction of chemokines with the extra-
cellular N terminus and loops of their cognate receptors (9, 10)
as well as by the activation state of the receptor (6).
In this study, we demonstrate that also the intracellular side
of the receptor, more particularly Hx8 in the C-tail of ORF74,
directs chemokine binding. Mutational analysis and receptor
modeling studies show that disruption of the intracellular Hx8
distorts the H-binding network crucial for positioning of the
transmembrane domains and interaction with Gq, thereby
inducing differential chemokine binding to ORF74. Thus, posi-
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tioning of Hx8 of ORF74 appears to be a key determinant in
directing chemokine binding.
EXPERIMENTAL PROCEDURES
Materials—Cell culture media, penicillin, and streptomycin
were obtained from Invitrogen, and fetal bovine serumwas pur-
chased from Integro B.V. (Dieren, The Netherlands). myo-[2-
3H]Inositol (17Ci/mmol) and 125I-labeledCXCL1,CXCL8, and
CXCL10 (2,200 Ci/mmol) were obtained from PerkinElmer
Life Sciences. Chemokines were obtained from PeproTech
(Rocky Hill, NJ).
DNAConstructs—The cDNAof theHHV-8-encodedORF74
(GenBankTM accession number U71368 with a silent G 3 T
mutation at position 927) was a gift from T. Schwartz and
inserted in pcDEF3 (a gift from J. A. Langer (11)) after PCR
amplification.ORF74C-tail deletionmutantswere constructed
using PCR. Constructs were tagged at the N terminus with the
influenza virus hemagglutinin (HA) epitope using PCR or sub-
cloning. pEGFP-N1 constructs containing cDNA encoding
ORF74-WT, 12, and 24 have been described before (12).
pSG5-ORF74-R322W and -Q323P were previously described
(13). The NF-B reporter plasmid pNF-B-Luc was obtained
from Stratagene (La Jolla, CA).
Cell Culture and Transfection—COS-7 cells were grown at
5% CO2 at 37 °C in Dulbecco’s modified Eagle’s medium sup-
plemented with 5% fetal bovine serum, penicillin (50 IU/ml),
and streptomycin (50 g/ml). COS-7 cells were transiently
transfected with 2 g of ORF74 construct or empty vector
(mock transfection) per million cells using DEAE-dextran.
ELISA—COS-7 cells were transfected with cDNA encoding
HA-tagged ORF74 constructs or empty vector (mock transfec-
tion). Forty-eight hours after transfection, cells were washed
with Tris-buffered saline and fixed with 4% paraformaldehyde
in phosphate-buffered saline. After blocking with 1% skimmilk
in 0.1 M NaHCO3 (pH 8.6), cells were incubated with mouse
monoclonal anti-HA antibody (a gift from J. van Minnen) in
Tris-buffered saline containing 0.1% bovine serum albumin,
washed three times with Tris-buffered saline, and incubated
with goat anti-mouse horseradish peroxidase-conjugated sec-
ondary antibody (Bio-Rad). Subsequently, cells were incubated
with substrate buffer containing 2 mM o-phenylenediamine
(Sigma), 35 mM citric acid, 66 mMNa2HPO4, 0.015% H2O2 (pH
5.6). The reaction was stopped with 1 MH2SO4, and absorption
at 490 nm was determined.
Confocal Imaging—Transfected COS-7 cells were grown on
glass coverslips. After 48 h, confocal images were collected at a
wavelength of 488 nm and processed as described previously
(14).
Phospholipase C Activation—Twenty-four h after transfec-
tion, COS-7 cells were labeled overnight in Earle’s inositol-free
minimal essential medium supplemented with myo-[2-3H]-
inositol (2 Ci/ml). Cells were washed with Dulbecco’s modi-
fied Eagle’s medium containing 20 mM LiCl and 25 mM HEPES
(pH 7.4) and incubated for 2 h in the same medium in the
presence or absence of indicated chemokines (100 nM). Inositol
phosphates were isolated as described previously (15) and
counted by liquid scintillation.
NF-B Reporter Gene Assay—COS-7 cells were co-trans-
fected with pNF-B-Luc (5 g/106 cells) and indicated ORF74
constructs (2 g/106 cells). Transfected cells were seeded in
96-wellwhite plates (Costar) in serum-free culturemediumand
incubated with the indicated chemokines (100 nM) for 48 h,
after which NF-B-driven luciferase expression was measured
by aspiration of the medium and the addition of 25 l of lucif-
erase assay reagent (0.83mMATP, 0.83mMD-luciferin, 18.7mM
MgCl2, 0.78MNa2H2P2O7, 38.9 mMTris (pH 7.8), 0.39% (v/v)
glycerol, 0.03% (v/v) Triton X-100, and 2.6 M dithiothreitol).
Luminescence was measured for 3 s in a Wallac Victor2.
Binding Experiments—Transfected COS-7 cells were seeded
in 48-well plates. After 48 h, binding was performed on whole
cells for 4 h at 4 °C using 125I-labeled chemokines (100 pM) in
binding buffer (50 mM HEPES (pH 7.4), 1 mM CaCl2, 5 mM
MgCl2, 0.5% bovine serum albumin) in the presence or absence
of unlabeled chemokine. After incubation, cells were washed
three times with ice-cold binding buffer supplemented with 0.5
MNaCl. Subsequently, cells were lysed and counted in aWallac
Compugamma counter. Total protein per well was determined
with lysed cells using the BCA protein assay (Pierce).
Construction of the ORF74 Receptor Model—A model of
the ORF74 receptor was constructed by homology modeling
using the crystal structure of rhodopsin (Protein Data Bank
code 1U19) (16) as template. The following amino acids were
aligned: N55-N1.5065 (the superscripts represent the residue
numbering in the rhodopsin structure and ORF74 sequence,
respectively, and 1.50 is the standardized numbering for
GPCRs according to Ballesteros and Weinstein (17), based
on the most conserved amino acid in each TM helix). The
first number refers to the helix in which the amino acid is
located, and the second number indicates the position relative
to themost conserved amino acid at position 50 in that helix, i.e.
N1.50, D2.50, R3.50, W4.50, P5.50, P6.50, and P7.50), N73-
D2.4083, R135-R3.50143, P215-P5.50223, P267-P6.50266, and P303-
P7.50311. The absence of W4.50 in the ORF74 receptor makes
the orientation of TM4 arbitrary. The amino acids at the intra-
cellular C-terminal domain are numbered relative to P303-
P7.50311. Thus, the highly conserved Phe side chain in Hx8 is
F313-F7.60321. A detailed description of the procedure to obtain
the molecular models of wild type and mutant receptors has
been reported elsewhere (18).
RESULTS
Deletion of C-tail Does Not Affect ORF74 Expression—
ORF74-WT and C-tail deletion mutants of ORF74 (12 and
24 amino acids) were constructed (Fig. 1A). The constructs
were also tagged at the N terminus with the HA epitope or
C-terminally fused with enhanced green fluorescent protein
(EGFP) (12). All constructs were expressed at the cell surface to
a similar degree as wild type (WT) ORF74 in COS-7 cells, as
assessed by ELISA with a monoclonal anti-HA antibody (Fig.
1B). Confocal microscopic images of cells expressing ORF74-
WT-EGFP, 12-EGFP, and 24-EGFP confirmed that these
receptors show similar expression patterns (Fig. 1C).
Gq-mediated Signaling Is Modulated by Deletion of the
C-tail of ORF74—ORF74 activates phospholipase C (PLC) in
the absence of ligands through activation of Gq proteins (19–
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21). ORF74-12 was less efficient thanWT in constitutive acti-
vation of PLC, whereas ORF74-24 lacked all constitutive
activity (Fig. 2A). The level of activation of ORF74-12 by the
agonist CXCL1 was comparable withWT. In contrast, ORF74-
24 did not respond to CXCL1. The inverse agonist CXCL10
inhibited basal signaling of ORF74-WT and 12, whereas 24
was unaffected by incubation with CXCL10 as expected since
ORF74-24 did not display constitutive activity. Similar results
were obtained when ORF74-mediated NF-B activation was
measured using a NF-B-luciferase reporter gene (Fig. 2B).
These data indicate that the C-tail of ORF74 is important for
Gq-mediated signal transduction.
C-tail Directs Chemokine Binding Profile of ORF74—The
observed reduction in constitutive signaling could be a conse-
quence of the expression of improperly folded receptors, which
cannot be discriminated from functional receptors by the
ELISA and confocal microscopy experiments shown in Fig. 1.
Therefore, binding experiments with the radiolabeled neutral
ligandCXCL8were performed. 125I-CXCL8 binding toORF74-
12 was reduced when compared with WT (Fig. 3A). More-
over, ORF74-24 did not bind 125I-CXCL8 at all. Similar exper-
iments were performed with the radiolabeled inverse agonist
CXCL10. Surprisingly, a gradual increase in 125I-CXCL10 bind-
ing was observed upon deletion of C-terminal amino acids
when compared withWT (Fig. 3A). ORF74-24, which did not
bind 125I-CXCL8, showed the most pronounced increase in
125I-CXCL10 binding.
Bindingwith the radiolabeled agonist CXCL1was unaffected
for ORF74-12 or24 (Fig. 3B). Furthermore, the affinity of all
tested chemokines for the deletionmutants did not change sig-
nificantly when compared with ORF74-WT, as determined
with homologous displacement curves (Fig. 3, C–E). Interest-
ingly, different numbers of binding sites were obtained for the
radiolabeled chemokines. ForCXCL8, the observedBmax varied
between300 (WT) and 0 (24) fmol/mg of protein. The Bmax
values for CXCL1 and CXCL10 were about 10-fold higher in
the 1–5 pmol/mg of protein range. Notably, Bmax values for
CXCL1 were consistently higher than for CXCL10. Therefore,
it appears that the C-tail of ORF74 influences the chemokine
binding profile of ORF74.
Chemokine Binding Profile of ORF74 Correlates with Proper
Gq Interaction—We previously showed that several residues
of the C-tail distal to the seventh transmembrane domain affect
functional G-protein coupling (13). In particular, the ORF74-
R322W mutant (R7.61322W, according to the standardized
GPCR numbering (17), see “Experimental Procedures”) was
unable to couple functionally toGq in the absence of ligands in
HEK293 cells. Anothermutant,ORF74-Q323P (Q7.62323P), was
FIGURE 1. Expression ofORF74deletionmutants.A, schematic representa-
tion of the C-tail of ORF74-WT and mutants. Residues downstream of the
conserved Pro at the end of TM7 (P7.50311) are shown. R7.61322 and Q7.62323
are shown in bold. The region conserved among -herpesvirus GPCRs is
depicted in italics, andHx8 is underlined. B, ELISAwith HA-tagged. COS-7 cells
were transfected with cDNA encoding N-terminally HA-tagged ORF74 con-
structs or empty vector. Forty-eighthours after transfection, expressionof the
HA-tagged receptors was determined using an anti-HA antibody in an ELISA.
Data are presented as the percentage of the absorption displayed by mock-
transfected (mock) cells. A representative experiment performed in triplicate
is shown. The experiment was repeated three times. C, confocal microscopy
with EGFP-tagged ORF74. Representative pictures of COS-7 cells were made
after transfection with C-terminally EGFP-tagged ORF74 constructs.
FIGURE 2. Signal transduction of ORF74 deletionmutants. A, activation of
PLC. COS-7 cellswere transfectedwithHA-taggedORF74 constructs or empty
vector. After 48 h, inositol phosphates accumulation was determined for 2 h
in the absence (black bars) or presence of 100 nM CXCL1 (white bars) or
CXCL10 (gray bars). mock, mock-transfected. B, activation of NF-B. COS-7
cells were cotransfected with pNF-B-Luc and HA-tagged ORF74 constructs
or empty vector and incubated in the presence or absence of chemokines
(100 nM). NF-B-mediated luciferase expression was determined after 48 h.
Data are presented as the percentage of unstimulated mock-transfected
cells. Representative experiments performed in triplicate are shown. The
experiments were repeated three times.
Helix 8 of ORF74 Directs Chemokine Binding
NOVEMBER 17, 2006•VOLUME 281•NUMBER 46 JOURNAL OF BIOLOGICAL CHEMISTRY 35329
 at Vrije Universiteit, Medical Library, on December 21, 2011
w
w
w
.jbc.org
D
ow
nloaded from
 
unable to constitutively activate both Gq- and Gi-mediated
signaling pathways in HEK293 cells (13) (Fig. 1A). In this study,
we further analyzed the effect of these mutations on signaling
and chemokine binding properties. Both ORF74-R322W and
-Q323P mutants were unable to constitutively activate PLC in
COS-7 cells (Fig. 4A), consistent with their inability to consti-
tutively activate Gq. However, ORF74-R322W activated PLC-
mediated signaling when incubated with the agonist CXCL1,
whereas ORF74-Q323P did not activate PLC in the presence of
CXCL1. The inverse agonist CXCL10 inhibited constitutive
signaling of WT, and signaling of the constitutively inactive
mutants was unaffected by CXCL10 as expected. Next, we
investigated activation of NF-B by both point mutants.
ORF74-R322W and ORF74-Q323P did not constitutively acti-
vate NF-B in COS-7 cells (Fig. 4B). However, both mutants
could be stimulated with CXCL1 in this assay, although activa-
tion ofNF-BbyORF74-Q323Pwas onlymarginal. As expected,
no effect on signaling of the inactive mutants was observed for
the inverse agonist CXCL10 (Fig.
4B). Subsequently, binding experi-
ments with radiolabeled CXCL8,
CXCL10, and CXCL1 were per-
formed. Similar to ORF74-12,
ORF74-R322W displayed a reduced
number of CXCL8 binding sites,
whereas the number of CXCL10
binding sites was increased when
compared with WT (Fig. 5A). As
seen for ORF74-24, ORF74-Q323P
did not bind CXCL8 at all, although
it showed more binding sites for
CXCL10 when compared with WT
(Fig. 5A). All receptors had a com-
parable number of binding sites for
CXCL1 (Fig. 5B). The observed
changes in the amount of CXCL8
and CXCL10 binding could not be
explained by a change in affinity of
the ligands for the mutants (Fig. 5,
C–E) but was a result of a change in
the number of binding sites. Sum-
marizing, the ability of the C-tail of
ORF74 to functionally interact with
Gq correlates with its chemokine
binding profile.
ORF74 C-tail Directs the Number
of Binding Sites Accessible to Each
Individual Ligand—Both CXCL1
and CXCL10 bind with high affinity
to a common conformation of the
receptor or to readily interconvert-
ible states, not available for CXCL8
(3). We therefore determined
whether the change in the number
of binding sites for CXCL8 and
CXCL10 could be explained by a
change in the number of receptor
states that are accessible for these
ligands. To this end, heterologous displacement experiments
were performed with the mutants that showed the most
extreme differences in chemokine binding when compared
with ORF74-WT, i.e. 24 and Q323P. Interestingly, although
CXCL8 andCXCL10 could not effectively displace 125I-CXCL1
from ORF74-WT, CXCL10 could displace part of the bound
125I-CXCL1 from the constitutively inactive mutants ORF74-
24 and -Q323P (Fig. 6A). All chemokines could effectively dis-
place 125I-CXCL8 from ORF74-WT (Fig. 6B). Heterologous
displacement of 125I-CXCL8 from the ORF74-24 and -Q323P
mutants could not be performed since they do not bindCXCL8.
CXCL8 could not effectively displace 125I-CXCL10 from
ORF74-WT, -24, or -Q323P (Fig. 6C). In contrast, CXCL1
could displace 125I-CXCL10 effectively from all mutants (Fig.
6C), even from ORF74-24 and -Q323P, which showed an
increase in total 125I-CXCL10 binding (Figs. 3A and 5A, respec-
tively). Summarizing, the binding sites of 125I-CXCL1 and 125I-
CXCL10 are not available for CXCL8. Furthermore, the num-
FIGURE 3. Chemokine binding profile of ORF74 deletion mutants. COS-7 cells were transfected with the
indicated HA-tagged ORF74 constructs. A, binding experiments with 125I-labeled CXCL8 (black bars, left axis)
and CXCL10 (white bars, right axis) were performed in the absence (total binding) or presence (unspecific
binding) of unlabeled homologous chemokine (100 nM). B, binding experiments with 125I-CXCL1 were per-
formed in the absence (total binding) or presence (unspecific binding) of unlabeled CXCL1 (100 nM). Data are
presented as specific binding (total binding  unspecific binding) in cpm. C–E, homologous displacement
curves were generated in the presence of increasing concentrations of unlabeled chemokine. Data are pre-
sented as the percentage of total binding of each construct. For CXCL8, pIC50 values (the negative log of the
concentration of cold ligand at which the amount of bound radioligand is reducedwith 50%) were 8.6 and 8.8
forORF74-WTand12, respectively. ThepIC50 value for24 couldnotbedetermined since thismutant didnot
bind 125I-CXCL8. pIC50 values for CXCL10 were 8.5, 8.5, and 8.4 for WT, 12, and 24, respectively. For CXCL1,
the pIC50 values were 7.9, 8.1, and 8.1, respectively, for WT, 12 and 24. Representative experiments per-
formed in triplicate are shown. The experiments were repeated at least two times.
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ber of 125I-CXCL1 binding sites that are accessible for CXCL10
differs between ORF74-WT and both mutants, indicating a
shift in receptor states for the mutants.
ORF74 Model Predicts a Key Role for Hx8 in Receptor
Stabilization—To explain the observed changes in chemokine
binding properties upon alteration of the C-tail, a receptor
model based on the crystal structure of rhodopsin (16) was con-
structed. The membrane-proximal residues of the C-tail are
part of the predictedHx8 ofORF74 (Fig. 1A, underlined). Fig. 7,
A and B, show TM7 (blue, up to C7.55316), Hx8 that expands
parallel to themembrane (dark red, from L7.59320 to Q7.69330),
and the following C-tail that changes direction to cover Hx8
(S7.70331-T7.81342). TheORF74-12mutant lacks theC-tail up
toHx8,whereasORF74-24 does no longer possessHx8 (Fig. 7,
A and B).
The stability of -helices is achieved by the hydrogen bond
between the carbonyl oxygen of residue i to the N–H amide
atoms of residue i4 in the following turn of the helix. Notably,
the backbone carbonyl oxygens of residues at positions S7.54315
and C7.55316 do not possess their backbone N–H counterparts
because they are located at the bottom of TM7 (Fig. 7B).
Instead, the polar head group of R7.61322 stabilizes these free,
helix-ending carbonyls through hydrogen bond interactions
(Fig. 7B). The transition fromTM7, perpendicular to themem-
brane, to Hx8, parallel to the membrane, is accomplished
through the non-helical amino acids at positions L7.56317-
S7.58319. S7.58319 contains the first backbone carbonyl engaged
in the intramolecular hydrogen bond network that stabilizes
Hx8 (Fig. 7A). The electronic nature of the carbonyl oxygen
allows the formation of a hydrogen bond with both the N–H
group of the residue in the following turn of the helix and the
side chain of Q7.62323 in ORF74 (Fig. 7A). When Q7.62323 is
mutated to Pro (ORF74-Q323P), this interaction cannot take
place (Fig. 7C).
Fig. 7D shows the interaction of Y7.53314 in TM7 with
F7.60321 in Hx8 and with D2.4083 in TM2. The residues Y7.53
and F7.60 are highly conserved in the rhodopsin family of
GCPRs (92 and 68%, respectively) and form the NPXXYX5,6F
motif (22). The Asp (D2.4083) at the intracellular boundary of
TM2 is conserved among chemokine receptors and has previ-
ously been shown to affect signaling of ORF74 (23). The
hydroxyl group of Y7.53314 forms hydrogen bonds with the O
group and the carbonyl oxygen (via a water molecule) D2.4083
in TM2 (Fig. 7D).
DISCUSSION
The recent x-ray structure of rhodopsin, the prototype of
class A receptors, revealed the presence of a highly conserved
amphipathic eight helix (24). Based on this x-ray structure, it
has been predicted thatHx8 interacts with theN-terminal helix
of G and G subunits (25), implying its involvement in
G-protein coupling. Although for some GPCRs, Hx8 appears
dispensable for signaling (26), the importance of Hx8 in G-pro-
tein interaction has been shown, e.g. for the oxytocin receptor
(27), bradykinin receptors (28), the angiotensin II receptor type
1A (29), the leukotriene B4 receptor (30), and the1-adrenergic
receptor (31). Moreover, the N-terminal portion of Hx8 of the
protease-activated receptor PAR1 was found to be involved in
coupling to Gq, through a network of H-bond and ionic inter-
actions, connecting Hx8 to the conserved NPXXYX5,6F motif
on TM7 and also to the adjacent intracellular loop 1 (32).
In this study, we show that Hx8 of ORF74 is an important
determinant for constitutive activity, and more importantly,
chemokine binding, using functional, binding, and computa-
tional approaches. Deletion of up to 12 amino acids of theC-tail
resulted in reduced constitutive activation of PLC and NF-B
but not of agonist activation by CXCL1 (Fig. 2). Deletion of the
entire C-tail including Hx8, however, resulted in a completely
inactive receptor. The gradual loss of constitutive activity of
ORF74-12 and 24 was accompanied by a striking reduction
in binding sites for CXCL8 and an increase in binding sites for
CXCL10 (Fig. 3A). We therefore hypothesized that impaired
coupling to Gq caused the change in the chemokine binding
pattern of ORF74. To test this hypothesis, we used ORF74-
mutants (R322W and Q323P) in a region of the C-tail that is
conserved in -herpesvirus-encoded GPCRs (Fig. 1A). Some of
the amino acids in this region are also conserved in cellular
chemokine receptors (13). We have previously shown in
HEK293 cells that both mutants were unable to constitutively
activate Gq-mediated signaling pathways and that R322W
could not couple functionally to Gq, although R322W andGq
were still able to physically interact (13). Also in COS-7 cells,
FIGURE 4. Signal transduction of ORF74-R322Wand -Q323P. A, activation of
PLC. COS-7 cells were transfected with ORF74 constructs or empty vector.
After 48 h, inositol phosphates accumulation was determined for 2 h in the
absence (black bars) or presenceof 100nMCXCL1 (white bars) or CXCL10 (gray
bars). mock, mock-transfected. B, activation of NF-B. COS-7 cells were
cotransfected with pNF-B-Luc and ORF74 constructs or empty vector and
incubated in the presence or absence of chemokines (100 nM). NF-B-medi-
ated luciferase expression was determined after 48 h. Data are presented as
the percentage of unstimulated mock-transfected cells. Representative
experiments performed in triplicate are shown. The experiments were
repeated three times.
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ORF74-R322W and -Q323P did not constitutively activate Gq-
mediated signal transduction pathways (Fig. 4). However, when
stimulated with CXCL1, ORF74-R322W activated PLC and
NF-B, indicating that ligand-induced Gq activation for
R322W is still intact. In contrast, ORF74-Q323P could not acti-
vate PLC upon stimulation with CXCL1 (Fig. 4A), and CXCL1
only marginally stimulated NF-B through ORF74-Q323P (Fig.
4B), demonstrating that ORF74-Q323P is deficient in activating
Gq. The marginal activation of NF-B upon CXCL1 stimula-
tion ofORF74-Q323Pmight be ascribed to the high sensitivity of
the NF-B assay or due to coupling to other G-proteins as
G12/G13 that have been shown to be involved in ORF74-
mediated signaling (33). ORF74-R322W showed reduced
CXCL8 binding, whereas Q323P was devoid of CXCL8 binding.
Thus, the mutants that showed a reduction but not a complete
loss of CXCL8 binding have reduced (12) or no (R322W) con-
stitutive Gq-mediated signaling, but both have intact ligand-
induced Gq-mediated signaling (Figs. 2 and 4). The mutants
that showed a complete loss of CXCL8binding (24 andQ323P)
show no Gq-mediated signaling at all (Figs. 2 and 4). There-
fore, we explain the drop in CXCL8 binding as a result of a
decreased (12 and R322W) or
impaired (24 and Q323P) ability to
functionally interact with Gq.
Based on these findings, we sug-
gest that the neutral ligand CXCL8
only binds to a constitutively active
receptor conformation that has to
be able to functionally couple to
Gq proteins (R*Gq) (Fig. 8). The
increase in the number of CXCL10-
binding sites of themutants is due to
a shift from active (R*Gq) to inac-
tive (R) receptor conformations.
Being an inverse agonist, CXCL10 is
predicted to preferably bind to inac-
tive receptor conformations (34).
This hypothesis is confirmed by the
data in Fig. 6A where CXCL10 dis-
places 125I-CXCL1 from the inac-
tive mutants 24 and Q323P but not
from WT. The inability of CXCL10
to efficiently displace 125I-CXCL1
fromORF74-WT (Fig. 6A) indicates
an intermediate receptor state (R*)
that is accessible to CXCL1 but not
to CXCL10 (Fig. 8). Alternatively,
CXCL1 andCXCL10may bind in an
allotopicmanner to the same recep-
tor state, as was suggested for the
binding of CXCL10 and CXCL11 to
CXCR3 (6). The number of binding
sites of the agonist CXCL1 for all
mutants is comparable with WT,
suggesting that CXCL1 binds to all
receptor conformations and that
loss of binding to active receptor
conformations is compensated by
binding to inactive conformations. ORF74-12 displays some
constitutive activity and CXCL8 binding, although Hx8 is still
present in this mutant. However, it can be envisioned that dele-
tion of the last 12 amino acids already destabilizes Hx8 and its
interactions with Gq, resulting in a phenotype that mostly
exists in the R andR* states, and to a lesser extent, in theCXCL8
binding R*Gq state.ORF74-Q323P orORF74-24 do not func-
tionally interact with Gq at all and are predicted to be mainly
in the inactive R state that does not bind CXCL8.
We have previously reported that ORF74-5 fused to EGFP
is unable to activate NF-B and AP-1 in HEK293 cells (12).
Moreover, NIH-3T3 cells expressing ORF74-5-EGFP lacked
surface-independent growth in soft agar, in contrast to ORF74-
WT-EGFP, although ORF74-5-EGFP still induced secretion
of vascular endothelial growth factor comparable with
ORF74-WT in these cells (12). However, both ORF74-5 (data
not shown) and the shorter variant ORF74-12 (Fig. 2) are still
capable of constitutively activating NF-B and PLC in COS-7
cells. This indicates thatORF74-5-EGFPmight be defective in
certain signaling pathways in HEK293 and NIH-3T3 cells,
FIGURE 5. Chemokine binding profile of ORF74-R322W and -Q323P. COS-7 cells were transfected with indi-
cated ORF74 constructs. A, binding experiments with 125I-labeled CXCL8 (black bars) and CXCL10 (white bars)
were performed in the absence (total binding) or presence (unspecific binding) of unlabeled homologous
chemokine (100 nM). B, binding experiments with 125I-CXCL1were performed in the absence (total binding) or
presence (unspecific binding) of unlabeled CXCL1 (100 nM). Data are presented as specific binding (total
binding unspecific binding) in cpm. C–E, homologous displacement curves were generated in the presence
of increasing concentrations of unlabeled chemokine. Data are presented as thepercentageof total bindingof
each construct. The pIC50 values for CXCL8 were 8.6 and 8.5 for ORF74-WT and -R
322W, respectively. The pIC50
value for Q323P could not be determined since this mutant did not bind 125I-CXCL8. For CXCL10, the pIC50
values were 8.6, 8.3, and 8.4 for ORF74-WT, -R322W, and -Q323P, respectively. For CXCL1, the pIC50 values were
8.3, 8.0, and 8.2, respectively, forWT, R322W, andQ323P. Representative experiments performed in triplicate are
shown. The experiments were repeated at least two times.
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either due to their distinct cellular context or due to the pres-
ence of a C-terminal EGFP tag.
Fig. 7D shows the interaction of Y7.53314 in TM7 with
F7.60321 inHx8. These residues are part of the highly conserved
NPXXYX5,6Fmotif (22). It has been suggested that this aromat-
ic-aromatic interaction is disrupted during receptor activation,
leading to a proper realigning of Hx8 (22, 35). We suggest, on
the basis of our observations and previous work by others (32,
36), that additional interactions betweenTM7andHx8 are nec-
essary to maintain these helices at the proper orientation for
constitutive activity and chemokine binding. The R7.61322 side
chain of ORF74 interacts with the carbonyl groups of residues
S7.54315 and C7.55316 located at the end of TM7 (Fig. 7B). We
speculate that the absence of this interaction in the R7.61322W
mutant within Hx8 modifies TM7 and the binding site for che-
mokines at the extracellular part of the receptor. Position 7.61 is
conserved in the rhodopsin-like family of GPCRs, holding a
positively charged residue in 71% of the sequences (Lys, 17%;
Arg, 54%) and a polar Gln side chain in other 11% of the
sequences (37). All these polar side chains can form hydrogen
bond interactions with both backbone carbonyls. We propose
that the conserved side chain at position 7.61 has a specific role
both in stabilizing the end of TM7 and in aligning Hx8 relative
to the helical bundle of TM7 in the rhodopsin-like family of
GPCRs.
The intramolecular hydrogen bond between the backbone
carbonyl oxygen of residue S7.58319 at the beginning ofHx8 and
Q7.62323 through both its backbone N–H amide and its side
chain (Fig. 7A) seems another important element in defining
the conformation of Hx8 relative to the helical bundle. Position
7.62 is partially conserved in the rhodopsin family of GPCRs
since it contains a positively charged residue in 46% of the
FIGURE 6.Heterologous chemokine displacement. COS-7 cells were trans-
fected with indicated ORF74 constructs. After 48 h, heterologous displace-
ment experimentswereperformedwith radiolabeledCXCL1 (A), CXCL8 (B), or
CXCL10 (C) in the absence (black bars, total binding) or presence of 100 nM
cold CXCL1 (white bars), cold CXCL8 (spotted bars), or cold CXCL10 (gray bars).
ND, not determined since ORF74-24 and -Q323P do not bind 125I-CXCL8.
Representative experiments performed in triplicate are shown. The experi-
ments were repeated at least two times.
FIGURE 7. The microenvironment of TM7. Shown are TM7 (blue, up to
C7.55316), Hx8 that expands parallel to themembrane (dark red, fromL7.59320
to Q7.69330), and the following C-terminal tail that changes the direction to
cover Hx8 (S7.70331-T7.81342). The positions in which ORF74-12 and 24
were truncated are shown. A, a detailed view of the hydrogen bond interac-
tions between the carbonyl oxygen of S7.58319 at the beginning of Hx8 and
Q7.62323 through both its backbone N–H amide and polar side chain. B, the
interaction of the polar head group of R7.61322 with the free, helix-ending
carbonyl groups of residues S7.54315 and C7.55316 located at the end of TM7.
C, replacement of Q7.62323 by Pro in the Q7.62323P mutation removes both
the polar side chain and the backbone N–H group, preventing the formation
of any type of intramolecular hydrogen bond interaction. D, the interactions
of Y7.53314 in TM7 with D2.4083 in TM2 (goldenrod) and F7.60321 in Hx8.
FIGURE 8. Model for chemokine binding to ORF74 receptor states. The
uncoupled inactive receptor state R, the active state R*, and the active recep-
tor state coupled to Gq, R*Gq, are shown. Possible interactions with other
G-proteins are not shown for simplicity. The number of receptors in state R is
larger than the number of receptors in state R*Gq. CXCL1 binds to all recep-
tor states, whereas CXCL10 displaces CXCL1 only from R and R*Gq and
CXCL8 only binds to R*Gq. Upon gradual deletion of the C-tail as well as for
ORF74-R322W and -Q323P, a shift takes place in favor of the inactive R confor-
mation (bold arrow), resulting in a loss of R* and R*Gq conformations. There-
fore, the number of CXCL8 binding sites decreases, and the number of bind-
ing sites recognized by CXCL10 increases. The number of binding sites for
CXCL1, which has affinity for all states, remains constant.
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sequences (Lys, 20%; Arg, 26%) and a polar side chain in other
24% of the sequences (Ser, 5%; Thr, 2%; Asn, 7%; Gln, 7%; His,
3%) (37). Notably, the Q7.62323P mutation introduces a Pro-
kink (38) in Hx8, removing both the polar side chain and the
backbone N–H hydrogen bond interaction with the backbone
carbonyl oxygen of residue S7.58319 (Fig. 7C). Most likely, the
Q7.62323Pmutationmodifies the conformation of R7.61322 and
its interaction with the carbonyl groups at the end of TM7 (Fig.
7B), and of F7.60321 and its interaction with Y7.53314 in TM7
(Fig. 7C). In addition, the hydroxyl group of Y7.53314 forms
hydrogenbondswith theO group and the carbonyl oxygen (via
a watermolecule) of the partly conservedD2.4083 in TM2 (Asn,
40%; Asp, 10%), which has been proposed to play an important
role in ORF74 signaling (23). Interestingly, D2.40 is conserved
among most chemokine receptors, indicating a possible com-
mon intramolecular network. Variation of these key intracellu-
lar interactions between TM7, TM2, and Hx8 modifies the
binding site for chemokines at the extracellular part of the
receptor. TheORF74-24 truncation completely removesHx8,
resulting in an inactive receptor that does not bind CXCL8.
Taken together, our results not only imply the importance of
Hx8 for Gq coupling but show that positioning of Hx8 directs
the chemokine binding profile of ORF74. Although a causative
link between the loss of Gq-mediated signaling and loss of
CXCL8 binding as proposed in Fig. 8 appears apparent, one
might not rule out the occurrence of separate phenomena. Dis-
ruption of the interaction of TM7 with Hx8 might interfere
with both CXCL8 binding and Gq coupling.
Our results clearly demonstrate that CXCL1, CXCL10, and
CXCL8 bind to distinct ORF74 receptor populations (Figs. 6
and 8), explaining the apparent differences in Bmax. Similar to
findings for CXCR3 (6), the CXCL8-accesible, G-protein cou-
pled state of ORF74 forms only a fraction of the total amount of
receptor. The peptide ligands of GPCRs such as CXCR2,
CXCR3, US28, and the NK1 receptor all show non-competitive
behavior and differences in Bmax in binding studies (4–7).
Sequence conservation implies that most class A GPCRs have
an intracellular Hx8 (25). The importance of Hx8, and in par-
ticular the H-bonding network involving the conserved residue
R7.61, in directing receptor-ligand interactionsmight therefore
be extrapolated to other class A GPCRs.
Additionally, G-proteins and adapter proteins (25, 39–42)
have been reported to bind to Hx8 or to the NPXXYX(5,6)F
motif (43). Binding of these proteins toHx8 or phosphorylation
of residues within Hx8 might influence its integrity and
H-bonding properties and thereby affect receptor-ligand inter-
actions. ORF74-mediated tumorgenesis is not only dependent
on constitutive activity of the receptor but also on regulation by
endogenously expressed chemokines (44). Since ORF74 cou-
ples to a variety of G-proteins, the G-protein expression profile
of infected cells might influence the relative amount of ORF74
in active and inactive conformations, thereby affecting the abil-
ity of individual chemokines to bind and signal efficiently. As
such, Hx8 and proteins binding to Hx8 appear crucial determi-
nants that direct not only signaling but also ligand binding.
Thus, the cellular context and phosphorylation state of chemo-
kine receptors might control chemokine binding properties
and limit the known apparent chemokine redundancy (2) in
general.
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